Lars Fruergaard Jørgensen, Novo Nordisk CEO (Nanna Navntoft/Bloomberg via Getty Images)
November 1, 2024 11:28 AM EDT
R&D

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

Max Bayer

Pharma Reporter

A day af­ter Madri­gal Phar­ma­ceu­ti­cals im­pressed in­vestors, No­vo Nordisk is look­ing to steal the spot­light.

The Dan­ish drug­mak­er re­port­ed Fri­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Ex­clu­sive: Blood stem cell ther­a­py mak­er Garu­da gets new CEO, adds $47M

Ex­clu­sive: Women’s health uni­corn Maven Clin­ic cuts 10% of its work­force weeks af­ter rais­ing $125M

FDA re­moves hold on three CARs­gen CAR-T tri­als; Ono pass­es on itolizum­ab

Bax­ter pulls IV prod­ucts out of Chi­na to shift sup­ply to the US

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

A service from the Financial Times